Thermo Fisher Scientific
In the development of biotherapeutics, a thorough understanding of a molecule’s product quality attributes (PQAs), and their effect on structure-function relationships and long-term stability, is key for ensuring the safety/efficacy of the product. At present, numerous routine chromatographic and electrophoretic assays are used to characterize and monitor individual PQAs for batch release, stability time-points and process/formulation development support. However, execution of multiple routine methods is time/resource intensive and often provides an indirect measure of biologically-relevant PQAs. Learn about an MS-based multi-attribute method (MAM) “Lab-of-the-Future,” that provides concurrent detection, identification, quantitation and quality control (monitoring) of PQAs.
Andrew Dawdy, Principal Scientist, Pfizer
Andrew received his PhD in Chemistry from the University of Virginia, where he performed research in protein characterization by mass spectrometry. He has spent the last six years working in pharmaceutical development, with the last four of those developing biotherapeutics at Pfizer. He is a principal scientist at Pfizer in their core mass spectrometry group within the “Biotherapeutics Pharmaceutical Sciences” division. For the last three years, he has worked as a member of Pfizer’s multi-attribute method (MAM) team.
* Required field